12 KOREAN STARTUPS SHOWCASE CUTTING-EDGE INNOVATIONS AT MUST CONNECT 2023 SINGAPORE

KUALA LUMPUR, Oct 16 (Bernama) -- Twelve promising Korean startups showcased their innovative products and growth plans to global pharmaceutical companies as well as investors at the MUST Connect 2023 Singapore roadshow, which was held on Oct 11 and 12 at Singapore Science Park.

Held for the second time, the roadshow helps Korean life science startups expand overseas by connecting them with global pharmaceutical companies and investors.

“Korean life science startups are gaining increasing attention with each passing year, given the enthusiastic response from attending companies and investors, we can expect to see concrete results emerge soon,” said MUST Accelerator Chief Executive Officer, Julia Lee in a statement.

The event kicked off with presentations on cutting-edge industry trends and open innovation initiatives by leading companies and hospitals, followed by investor pitches from the 12 Korean startups.

Among them were Neurophet, which uses artificial intelligence (AI) to analyse brain structures that vary from person to person; ImmunAbs, an autoimmune treatment that is set to enter phase two clinical trials in the United States next year; and ABLELabs, a manufacturer of bio-lab liquid handling robots that won second place in the Innovator's Pitch Challenge at RESI Boston September.

It also provided opportunities for startups to network with investors and potential collaborators, whereby personalised one-on-one meetings were held to facilitate discussions about investment and partnership opportunities.

Organised by Must Accelerator, 'Must Connect' is a roadshow to introduce Korean life science startups to major companies, hospitals and investors in Singapore, where the Asia Pacific offices of global pharmaceutical companies are concentrated.

The Incheon Free Economic Zone (IFEZ), which has been supporting Korean life science startups, participated as a sponsoring organisation.

-- BERNAMA